ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
9.32
+0.16 (1.75%)
At close: Jun 6, 2025, 4:00 PM
9.31
-0.01 (-0.11%)
After-hours: Jun 6, 2025, 4:33 PM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.
Employees
115
Change (1Y)
15
Growth (1Y)
15.00%
Revenue / Employee
n/a
Profits / Employee
-$1,155,278
Market Cap
662.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Dec 31, 2020 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ORIC News
- 8 days ago - ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
- 9 days ago - ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewsWire
- 9 days ago - ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - GlobeNewsWire
- 10 days ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire
- 5 weeks ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire